Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 9/20 | 0.64 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542325 | 1.00 | GRM7 (0.64) | GRM7KCNA5P2RX7STING1KMT2A | |
| SCHEMBL21542323 | 1.00 | GRM7 (0.64) | GRM7KCNA5P2RX7STING1KMT2A | |
| SCHEMBL21542195 | 0.84 | GRM7 (0.66) | GRM7P2RX7KMT2AMEN1 | |
| SCHEMBL20182781 | 0.84 | GRM7 (0.66) | GRM7P2RX7KMT2AMEN1 | |
| SCHEMBL20183016 | 0.84 | GRM7 (0.66) | GRM7P2RX7KMT2AMEN1 | |
| SCHEMBL21542196 | 0.84 | GRM7 (0.66) | GRM7P2RX7KMT2AMEN1 | |
| SCHEMBL21542290 | 0.84 | GRM7 (0.66) | GRM7P2RX7KMT2AMEN1 | |
| SCHEMBL21542288 | 0.84 | GRM7 (0.66) | GRM7P2RX7KMT2AMEN1 | |
| SCHEMBL30487148 | 0.84 | GRM7 (0.66) | GRM7P2RX7KMT2AMEN1 | |
| SCHEMBL21542311 | 0.83 | GRM7 (0.64) | GRM7P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| WO-2018092921-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | GRM7 1/4885KCNA5 1293/4885P2RX7 287/4885 |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | GRM7, GRM2, GRM1 | GRM7 1/4885KCNA5 1293/4885P2RX7 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.